HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $60

10/19/2026
Impact: 70
Healthcare

HC Wainwright & Co. analyst Patrick R. Trucchio has maintained a Buy rating on Alto Neuroscience (NYSE: ANRO) and raised the price target from $55 to $60. This adjustment reflects a positive outlook for the company's performance.

AI summary, not financial advice

Share: